Finasteride Tablet, Film Coated
Product Images NDC 68788-8749

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 68788-8749). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

This text refers to the results of a study comparing the symptom score over four years in two long-term efficacy and safety studies for a treatment with finasteride compared to a placebo. The mean change from baseline plus one standard error is likely provided for each time point. The data from each group may have been recorded for each year (Baseline, Year 1, Year 2, Year 3, Year 4).*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

This text provides information about the percent of patients having surgery for BPH (Benign Prostatic Hyperplasia) including TURP (Transurethral Resection of the Prostate). The data is presented in Figure 2, showing the percent of patients over time for both the Finasteride group and the Placebo group. The information includes the observation time in months, the number of events cumulative, and the number at risk per year for each group. This data can help in evaluating the effectiveness of Finasteride in reducing the need for surgery in patients with BPH.*

FDA Label Image

Figure3 (Finasteride Fig3)

The text shows a figure presenting the percentage of patients developing Acute Urinary Retention over time in a study comparing a group receiving Finasteride with a placebo group. The data displayed includes the observation time in months, the number of events cumulatively, as well as the number at risk per year for each group.*

FDA Label Image

Figure4 (Finasteride Fig4)

This text provides information on the mean percent change from baseline with ± 1 standard error in Prostate Volume in a Long-Term Efficacy and Safety Study. It shows the data for both the placebo group and the Finasteride treatment group over a span of 4 years. The values displayed represent the reduction in prostate volume over the years for both the groups.*

FDA Label Image

Figure5 (Finasteride Fig5)

This figure shows the cumulative incidence of a 4-point rise in the AUA Symptom Score by treatment group over several years from randomization. The y-axis represents the percentage of individuals experiencing the event, and the x-axis shows the years from randomization.*

FDA Label Image

Finasteride Tablets Usp 5mg (Finasteride Fig6)

This text provides information on Finasteride tablets, a generic for Proscar, containing 5mg of finasteride USP. It includes details such as package size, expiration date, manufacturer (Aurobindo Pharma Limited), product warnings, and storage instructions. The warning highlights that women and children should not use or handle finasteride tablets, emphasizing the importance of keeping medication out of reach of children. It also describes the tablet as round, blue, imprinted with E/61. The text advises against transferring the drug to anyone other than the prescribed patient due to federal law restrictions.*

FDA Label Image

Chemical Structure (Finasteride Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.